VA-CVENT
3.10.2018 13:02:12 CEST | Business Wire | Press release
Cvent , a market leader in meetings, events, and hospitality technology, today announced that renowned brand and long-time Cvent customer AccorHotels will utilize Cvent’s Business Transient solutions exclusively across their more than 4,500 hotels worldwide to more effectively manage their corporate travel programs. The announcement highlights AccorHotels’ continued commitment to their hotel partners to help them grow revenue and increase market share through Cvent’s industry-leading software solutions. Additionally, the two brands will collaborate on the creation of new technology that will help hospitality professionals worldwide better manage their travel programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181003005210/en/
“Eighty percent of Fortune 100 companies use Cvent technology, and more than 1.5 million RFPs were sourced through Cvent’s Business Transient platform in the last year, which indicates its indispensable role for both buyers and sellers in the corporate travel market. Properties that are able to fully leverage the platform to help them attract corporate buyers with smarter marketing solutions will ultimately generate more booked room nights,” said Kathleen Garcia, Vice President of Sales for Cvent’s Hospitality Cloud. “AccorHotels, one of Europe’s most recognized hospitality brands, has embraced this opportunity to grow their corporate travel programs across their thousands of hotels, and we are proud to be their exclusive business travel management solution. We look forward to supporting their continued success and working as a trusted partner to help them grow their MICE and corporate travel business worldwide.”
AccorHotels and their thousands of properties worldwide will gain access to Cvent’s complete suite of Business Transient tools to help them address their travel management needs. The solutions will help the properties better manage their RFP process, market to corporate travel buyers, and improve operational efficiency, facilitating future business transient growth. AccorHotels’ use of Cvent highlights the opportunity for leading hospitality brands to better manage their business travel needs.
Cvent and AccorHotels will also work together on the co-development of additional travel management capabilities that will focus on expanding transient sourcing features, creating the tools to give properties a more holistic view of rates across all market segments, and streamlining manual processes through deeper system integrations.
“We have worked with Cvent for 10 years and our properties have been very satisfied with the seamless workflow of Cvent tools both on MICE and corporate travel business,” said Agathe Fabron AccorHotels VP Business Travel & Meetings & Events. “Many of our properties have been using Cvent Business Transient for their travel needs and the positive impact we have seen thus far made the decision to roll it out worldwide very easy. We look forward to continuing this long-standing relationship and to work hand-in-hand with the Cvent team to drive our corporate travel business, and the industry, forward.”
About Cvent, Inc.
Cvent, Inc. is a leading meetings, events, and hospitality management technology provider with more than 3,500 employees, 25,000 customers, and 300,000 users worldwide. The Cvent Event Cloud offers software solutions to event planners for online event registration, venue selection, event management, mobile apps for events, email marketing, and web surveys. The Cvent Hospitality Cloud partners with hotels and venues to help them drive group/MICE and corporate travel business. Hotels use the Cvent Hospitality Cloud’s digital marketing tools and software solutions to win business through Cvent’s sourcing platforms and to service their customers directly, efficiently and profitably – helping them grow and own their business. Cvent solutions optimize the entire event management value chain and have enabled clients around the world to manage hundreds of thousands of meetings and events. For more information, please visit Cvent.com , or connect with us on Facebook , Twitter or LinkedIn .
About AccorHotels
AccorHotels is a world-leading travel & lifestyle group and digital innovator offering unique experiences in more than 4,500 hotels, resorts and residences across 100 different countries. With an unrivaled portfolio of internationally renowned hotel brands encompassing the entire range from luxury to economy, from upscale to lifestyle and midscale brands, AccorHotels has been providing savoir-faire and expertise for more than 50 years.
In addition to its core hospitality business, AccorHotels has successfully expanded its range of services, becoming the world leader in luxury private residence rental with more than 10,000 stunning properties around the world. The Group is also active in the fields of concierge services, co-working, dining, events management and digital solutions.
Relying on its global team of more than 250,000 dedicated staff, AccorHotels is committed to fulfilling its primary mission: to make every guest Feel Welcome. Guests have access to one of the world’s most attractive hotel loyalty programs - Le Club AccorHotels.
For more information or to make a reservation, please visit accorhotels.group or accorhotels.com. Or join and follow us on Twitter and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181003005210/en/
Contact:
Cvent, Inc. Erica Stoltenberg 571-378-6240 estoltenberg@cvent.com or Spotl1ght Communications Sam Pepper sam.pepper@spotlightcoms.com or Sharon Coleshill +44 (0) 208 334 4005 sharon.coleshill@spotlightcoms.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom